Olivier Loria

Dr. Olivier Loria


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Juliette THARIATJuliette THARIAT
Juliette THARIAT
LBLaurys BOUDIN
Laurys BOUDIN
OLOlivier Loria
Olivier Loria
ANAnh-Minh Nguyen
Anh-Minh Nguyen
Laurent KodjikianLaurent Kodjikian
Laurent Kodjikian
Thibaud MathisThibaud Mathis
Thibaud Mathis
Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient.